07:00 , Aug 13, 2012 |  BioCentury  |  Emerging Company Profile

Wilson Therapeutics: Clearing copper

Wilson Therapeutics AB is repurposing a metal-binding cancer compound into a therapy for Wilson's disease, a rare hereditary condition that leads to accumulation of toxic levels of copper. The compound, Decuprate, may be a safer...
07:00 , May 16, 2011 |  BC Week In Review  |  Clinical News

Vorinostat regulatory update

The European Commission granted Orphan Drug designation for Merck's vorinostat to treat multiple myeloma. Vorinostat is in Phase III testing for the indication. Merck markets the histone deacetylase (HDAC) inhibitor as Zolinza to treat advanced...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Company News

Mersana management update

Mersana Therapeutics Inc. , Cambridge, Mass.   Business: Cancer   Hired: Nicholas Bacopoulos, a director, as president and CEO, formerly president and CEO of Aton Pharma Inc. , now part of Valeant Pharmaceuticals International Inc....
00:56 , Sep 30, 2010 |  BC Extra  |  Company News

Mersana names Bacopoulos CEO

Cancer company Mersana Therapeutics Inc. (Cambridge, Mass.) hired Nicholas Bacopoulos, a director, as president and CEO. Previously, Bacopoulos was president and CEO of Aton Pharma Inc. , now part of Valeant Pharmaceuticals International (NASDAQ:VRX; TSX:VRX)....
07:00 , Jun 7, 2010 |  BC Week In Review  |  Company News

Aton, Valeant Pharmaceuticals International deal

Valeant acquired neurology and ophthalmology company Aton for $318 million in cash. Aton shareholders are eligible for undisclosed regulatory and sales-based milestones on undisclosed products. Valeant will retain global rights to the majority of Aton's...
07:00 , May 10, 2010 |  BC Week In Review  |  Company News

Aton, Bristol-Myers sales and marketing update

Bristol-Myers granted Aton Pharma exclusive rights to market Lodosyn carbidopa in the U.S. The aromatic amino acid decarboxylation inhibitor is approved for use with carbidopa-levodopa or with levodopa to treat symptoms of Parkinson's disease (PD)....
07:00 , Oct 5, 2009 |  BC Week In Review  |  Company News

Molecular Detection management update

Molecular Detection Inc. , Wayne, Pa.   Business: Diagnostics   Hired: Todd Wallach as CEO, formerly CFO of Aton Pharma Inc.  ...
07:00 , Mar 9, 2009 |  BC Week In Review  |  Company News

Aton, Merck sales and marketing update

Aton acquired exclusive rights to market Merck's Timoptic timolol line of ophthalmic products in the U.S. Financial terms were not disclosed. Timoptic is a non-selective adrenergic receptor beta blocker that is marketed to treat elevated...
08:00 , Feb 23, 2009 |  BC Week In Review  |  Clinical News

Vorinostat MSD vorinostat regulatory update

Merck withdrew an MAA for Vorinostat MSD vorinostat to treat advanced refractory cutaneous T cell lymphoma (CTCL). The company said it withdrew the application based on the view of the EMEA's CHMP that the data...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Clinical News

Zolinza vorinostat regulatory update

MRK submitted an MAA to EMEA for vorinostat to treat advanced refractory cutaneous T cell lymphoma (CTCL). MRK markets the HDAC inhibitor in the U.S. as Zolinza. MRK acquired the drug, which has Orphan Drug...